BIOMAT Database Logo BIOMAT Database Logo

Proliferative activity in primary breast carcinomas is a salient prognostic factor. 2004

Jean-Jacques Michels, and Jacques Marnay, and Thierry Delozier, and Yves Denoux, and Jacques Chasle
Department of Pathology, Centre François Baclesse, Caen, France. michels@baclesse.fr

BACKGROUND The goal of the current study was to investigate the prognostic impact of proliferative activity, together with the other classic clinicopathologic prognostic factors (tumor size, tumor grade, receptor status, ploidy, and lymph node status), in breast carcinoma by counting mitoses and evaluating S phase fraction (SPF) in fresh and frozen tumor samples. METHODS From March 1, 1990, to July 1, 1999, a total of 1984 previously untreated invasive breast carcinoma samples were snap-frozen for flow cytometry. RESULTS After multivariate analysis incorporating all classic prognostic factors, SPF combined with mitotic activity (i.e., proliferative activity) remained the sole prognostic factor in the lymph node-negative group; proliferative activity was accompanied by tumor size as a prognostic factor in patients with lymph node-positive disease and by lymph node status, lymphatic invasion, and receptor status in the overall population. The predictive value of proliferative activity was superior to that of the reference standards (classic prognostic predictors according to the guidelines of our institution [common oncology practice] and the St. Gallen classification). A review of the literature, focusing on series in which fresh material was used, allowed us to demonstrate that there is widespread agreement regarding the correlation between SPF and prognosis, even after multivariate analysis. CONCLUSIONS S phase fraction is a valuable predictor of survival and can confidently be assessed in approximately 80% of cases. In conjunction with mitotic activity, SPF should become a prognostic factor that is used in daily practice by oncologists for the management of breast carcinoma.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008940 Mitotic Index An expression of the number of mitoses found in a stated number of cells. Index, Mitotic,Indices, Mitotic,Mitotic Indices
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011336 Probability The study of chance processes or the relative frequency characterizing a chance process. Probabilities
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell

Related Publications

Jean-Jacques Michels, and Jacques Marnay, and Thierry Delozier, and Yves Denoux, and Jacques Chasle
Proliferative activity is a significant prognostic factor in male breast carcinoma.
August 1994, The American journal of pathology,
Jean-Jacques Michels, and Jacques Marnay, and Thierry Delozier, and Yves Denoux, and Jacques Chasle
MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas.
July 1995, The Journal of investigative dermatology,
Jean-Jacques Michels, and Jacques Marnay, and Thierry Delozier, and Yves Denoux, and Jacques Chasle
[Proliferative activity of tumor cells as a prognostic factor in breast cancer].
August 1995, Biulleten' eksperimental'noi biologii i meditsiny,
Jean-Jacques Michels, and Jacques Marnay, and Thierry Delozier, and Yves Denoux, and Jacques Chasle
FasL:Fas ratio--a prognostic factor in breast carcinomas.
February 2000, Cancer research,
Jean-Jacques Michels, and Jacques Marnay, and Thierry Delozier, and Yves Denoux, and Jacques Chasle
CD44v6 is not a prognostic factor in primary breast cancer.
January 1998, Annals of oncology : official journal of the European Society for Medical Oncology,
Jean-Jacques Michels, and Jacques Marnay, and Thierry Delozier, and Yves Denoux, and Jacques Chasle
[Evaluation of cellular proliferative activity and DNA ploidy as a prognostic factor in breast cancer].
January 1999, Minerva ginecologica,
Jean-Jacques Michels, and Jacques Marnay, and Thierry Delozier, and Yves Denoux, and Jacques Chasle
p53 protein expression and proliferative activity in ductal breast carcinomas.
August 2000, Cytopathology : official journal of the British Society for Clinical Cytology,
Jean-Jacques Michels, and Jacques Marnay, and Thierry Delozier, and Yves Denoux, and Jacques Chasle
SMAD4 is a potential prognostic marker in human breast carcinomas.
January 2014, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Jean-Jacques Michels, and Jacques Marnay, and Thierry Delozier, and Yves Denoux, and Jacques Chasle
HER2 borderline is a negative prognostic factor for primary malignant breast cancer.
May 2020, Breast cancer research and treatment,
Jean-Jacques Michels, and Jacques Marnay, and Thierry Delozier, and Yves Denoux, and Jacques Chasle
MDR1 gene expression and prognostic factors in primary breast carcinomas.
January 1991, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!